Body · topic 2 of 4
Body phenotyping
Metabolic syndrome screening, beyond BMI
Video walkthrough — Body Phenotyping
In production, coming soon
The Health Picture — weight × fitness
Normal · fitness above average
Lean & Active
Both dimensions in your favour. Strength work is the highest-value next add.
Normal · fitness low
Fit on the Outside
Normal weight, low fitness — and fitness is the bigger factor. Very changeable.
Overweight · fitness above average
Active & Heavy
Fitness is doing real protective work. Keep it while you address visceral fat.
Overweight · fitness low
Weight & Fitness Gap
Improve fitness first: risk reduction begins before the scale moves.
Obese · fitness above average
Strong Foundation
Fitness attenuates but does not eliminate the risk. Maintain it alongside change.
Obese · fitness low
Time to Move
1–2 METs from daily walking produces measurable mortality reduction.
Fitness is the axis that moves. The two together predict better than either alone, and a column of this grid can change within weeks of training while a row takes far longer — which is why the app leads with the tier rather than the weight.
Alberti et al. 2009 — Harmonizing the Metabolic Syndrome
Joint Scientific Statement from IDF, NHLBI, AHA, WHF, IAS, and IASO. Defines metabolic syndrome as any 3 of 5 criteria: waist circumference, fasting glucose, blood pressure, triglycerides, and HDL. Verve flags ≥1 abnormal criterion — intentionally more sensitive than the clinical ≥3 threshold — to surface early metabolic risk before full syndrome develops.
PMID 19560804 →
Wildman et al. 2008 — Metabolically Healthy Obese (NHANES)
Analysis of NHANES III data. Found that 31.7% of obese and 23.5% of overweight US adults are metabolically healthy — while 23.5% of normal-weight adults have ≥2 cardiometabolic risk abnormalities. Established that BMI alone is an unreliable proxy for metabolic health.
PMID 18695077 →
Thomas et al. 2012 — TOFI: Normal Weight, Hidden Fat (MRI/MRS)
MRI and magnetic resonance spectroscopy study. Demonstrated that individuals with normal BMI can carry substantial visceral and liver fat — the TOFI (Thin Outside, Fat Inside) phenotype. Visceral fat, not subcutaneous fat, drives the elevated metabolic risk.
PMID 22226027 →
Weight and BMI
Every weighing, the number every report asks for, and why it is not the first ratio Verve reads
What the app shows
Every weighing on file: Apple Health’s, and the weight typed in Settings dated the day it was set, one a day with Health’s winning. The card reads the latest, how it moved over four weeks, and twelve weeks as bars.
BMI is weight in kilograms divided by height in metres squared. It is worked out from each weighing and the height on the profile, never stored, so it cannot disagree with the weight it came from.
The two sets of lines
The WHO’s general cut-offs: under 18.5 underweight, 18.5 to 24.9 normal, 25 to 29.9 overweight, 30 and over obese.
For Asian adults, including South Asian, the WHO Expert Consultation of 2004 set action points lower, at 23 and 27.5, because risk rises at a lower BMI. The app uses these when the profile says so, the same rule its Body page applies to the metabolic criteria.
Why waist to height comes first
BMI moves with muscle as much as with fat: a person who trains can gain weight and lose fat in the same season and watch the number rise. Waist to height needs only a tape and a height, and it tracks the fat around the organs, which is the fat that carries the metabolic risk. Verve leads with it, and keeps BMI because every report, every clinic and every study still speaks in it.
Screening lines, not targets. What counts as a good number for you is a conversation with your doctor.
Body markers
What each measurement is, how to take it, the range it is read against, and how often it is worth repeating
These are screening bands, not treatment targets. What counts as a good number for you depends on your overall risk, and that is a conversation with your doctor. Verve classifies against population bands and says which study drew each line.
Ranges shown for a 50-year-old man of 175 cm; several move with sex, age, height or ancestry.
Blood sugar & insulin
Fasting blood sugarmg/dL
Blood sugar after an overnight fast
HbA1c is recorded separately — either one satisfies this criterion.
In range
- In range: < 100 mg/dL
- Elevated: ≥ 100 mg/dL
Repeat
every 3 years
yearly from 100 mg/dL
ADA Standards of Care 2026, §2
Line drawn by
Alberti et al. 2009 — harmonised metabolic syndrome criteria.
More on Fasting blood sugar ↓Less ↑
How to measure it
- Fast for 8 to 12 hours; water is fine, coffee is not.
- Have the blood drawn in the morning, before exercise.
- Enter the value as the lab printed it, in mg/dL.
HbA1c%
Your average blood sugar over the last three months
No fasting needed — it can be drawn at any time of day.
In range
- In range: < 5.7%
- Prediabetes: 5.7–6.4%
- Diabetes: ≥ 6.5%
Repeat
every 3 years
yearly from 5.7% · twice a year once treated and at goal, every 3 months when it is not
ADA Standards of Care 2026, §2 and §6
Line drawn by
American Diabetes Association — Standards of Care in Diabetes, Section 2.
More on HbA1c ↓Less ↑
How to measure it
- No fasting needed; any time of day.
- Ask for HbA1c by name on a routine panel.
- Enter the percentage as printed.
Post-meal glucosemg/dL
Blood sugar two hours after eating
Home glucometer reading, 1–2 hours after starting a meal.
In range
- In range: < 180
- Elevated: ≥ 180
Repeat
—
Line drawn by
American Diabetes Association, Standards of Care in Diabetes-2026, Section 6: Glycemic Goals, Hypoglycemia, and Hyperglycemic Crises (Diabetes Care 2026;49(Suppl 1):S132-S149). Peak postprandial self-monitoring target: <180 mg/dL.
More on Post-meal glucose ↓Less ↑
How to measure it
- Start the clock at the first bite of a usual meal.
- Test with a home meter one to two hours later.
- Enter in mg/dL; note what the meal was if it was unusual.
Fasting insulinuIU/mL
Fasting insulin, and the insulin resistance it implies
In range
—
Repeat
No schedule. It redraws whenever fasting insulin and fasting glucose are both on file.
No guideline schedules it
Line drawn by
No universally accepted single cutoff exists for HOMA-IR — results vary by population, assay, and lab. This threshold is derived from a Spanish cohort; some populations, including South Asian, tend to show insulin resistance at somewhat lower absolute values (MDCalc/NHANES-referenced range approximately 1.4-2.5). Not part of any validated management algorithm — a screening signal, not a diagnosis.
More on Fasting insulin ↓Less ↑
How to measure it
- Fast for 8 to 12 hours.
- Ask for fasting insulin alongside fasting glucose; HOMA-IR is worked out from the pair.
- Enter the insulin in uIU/mL as printed.
Blood pressure
Blood pressuremmHg
Systolic over diastolic, seated and rested
Two major guidelines classify blood pressure, and they genuinely disagree between 120 and 139 mmHg systolic. Verve classifies by whichever you choose — a toggle on the Blood pressure card — so the app agrees with the system your own doctor uses. Home readings are the preferred basis for both: an office reading can run higher (the white-coat effect), which is why Verve lets you tag where a reading was taken. Verve also reads your cuff's own log from Apple Health, so the average reflects every measurement, not just the ones typed in.
In range
- AHA/ACC 2017 — Normal: < 120 · Elevated: 120–129 · Stage 1 hypertension: 130–139 · Stage 2: ≥ 140
- ESC 2024 — Non-elevated: < 120 · Elevated: 120–139 · Hypertension: ≥ 140
- Metabolic-syndrome criterion (unchanged by the toggle): ≥ 130/85 counts toward the Alberti 2009 definition
Repeat
yearly under 120/80
3 to 6 months once above it · within a month from 140/90
Not all of this is the guideline’s — the within-a-month figure from 140/90 is Verve's own.
AHA/ACC 2017
Line drawn by
Whelton et al. 2017 (AHA/ACC) · McEvoy et al. 2024 (ESC) · Alberti et al. 2009.
More on Blood pressure ↓Less ↑
How to measure it
- Rest quietly for 5 minutes first — back supported, feet flat, legs uncrossed.
- Support your arm on a table so the cuff sits at heart level.
- No caffeine, exercise, or smoking in the 30 minutes before.
- Take 2 readings a minute apart and enter the average.
- Use the same arm each time you measure.
Lipids & inflammation
Triglyceridesmg/dL
Fat circulating in fasting blood
Fasting blood panel.
In range
- In range: < 150
- Elevated: ≥ 150
Repeat
every 4 to 6 years
4 to 6 weeks after starting or changing lipid-lowering treatment
One panel, one interval — ApoB, LDL, triglycerides and HDL come off the same blood draw.
AHA · USPSTF; on treatment, ESC/EAS 2019
Line drawn by
Alberti et al. 2009 — harmonised metabolic syndrome criteria.
More on Triglycerides ↓Less ↑
How to measure it
- Ask for a lipid panel; fasting is not required for most people, but do it the same way each time.
- Enter triglycerides in mg/dL as printed.
HDL cholesterolmg/dL
Cholesterol carried away from vessel walls
Fasting blood panel.
In range
- In range: ≥ 40
- Low: < 40
Repeat
every 4 to 6 years
4 to 6 weeks after starting or changing lipid-lowering treatment
One panel, one interval — ApoB, LDL, triglycerides and HDL come off the same blood draw.
AHA · USPSTF; on treatment, ESC/EAS 2019
Line drawn by
Alberti et al. 2009 — harmonised metabolic syndrome criteria.
More on HDL cholesterol ↓Less ↑
How to measure it
- Ask for a lipid panel; HDL is on every one.
- Enter in mg/dL as printed.
ApoBmg/dL
The particles that carry cholesterol into artery walls
ApoB counts atherogenic particles directly — one ApoB per LDL, IDL, VLDL and Lp(a) particle — so it captures risk that LDL-C alone can miss, particularly in insulin resistance and high triglycerides.
In range
- Optimal: ≤ 79
- Borderline: 80–99
- Elevated: > 99
Repeat
every 4 to 6 years
4 to 6 weeks after starting or changing lipid-lowering treatment
One panel, one interval — ApoB, LDL, triglycerides and HDL come off the same blood draw.
AHA · USPSTF; on treatment, ESC/EAS 2019
Line drawn by
ESC/EAS 2019 Guidelines for the Management of Dyslipidaemias (Mach F et al, Eur Heart J 2020;41:111-188). Risk-stratified ApoB goals: <65 mg/dL very-high risk, <80 mg/dL high risk, <100 mg/dL moderate risk. Verve screens against the <80 / <100 boundaries.
More on ApoB ↓Less ↑
How to measure it
- Ask for apolipoprotein B by name; it is not on a standard lipid panel.
- No fasting needed.
- Enter in mg/dL as printed.
LDL cholesterolmg/dL
Cholesterol on its way toward vessel walls
LDL cholesterol measures the cholesterol carried by LDL particles, not the particle count itself. Where the two disagree, ApoB is the better risk marker.
In range
- Optimal: ≤ 99
- Borderline: 100–129
- Elevated: > 129
Repeat
every 4 to 6 years
4 to 6 weeks after starting or changing lipid-lowering treatment
One panel, one interval — ApoB, LDL, triglycerides and HDL come off the same blood draw.
AHA · USPSTF; on treatment, ESC/EAS 2019
Line drawn by
NCEP ATP III (Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults, JAMA 2001;285:2486-2497). LDL-C classification: optimal <100, near-optimal 100-129, borderline-high 130-159, high 160-189, very high >=190 mg/dL. Verve collapses the upper bands into one 'elevated' tier for screening.
More on LDL cholesterol ↓Less ↑
How to measure it
- Ask for a lipid panel; LDL is on every one, calculated or measured.
- Enter in mg/dL as printed.
Lp(a)
An inherited particle that adds risk on its own
Lp(a) is ~90% genetically determined and stable through life — a single measurement is usually sufficient. Unit conversion between nmol/L and mg/dL is only approximate because it depends on apolipoprotein(a) isoform size; Verve stores the unit you entered and marks any converted value as approximate.
In range
- Low: ≤ 74 nmol/L · ≤ 29 mg/dL
- Intermediate: 75–124 nmol/L
- High: > 124 nmol/L · > 49 mg/dL
Repeat
—
Line drawn by
EAS 2022 Consensus Statement on lipoprotein(a) (Kronenberg F et al, Eur Heart J 2022;43:3925-3946). Risk rises continuously; commonly cited bands are <75 nmol/L (~<30 mg/dL) low, 75-125 nmol/L (30-50 mg/dL) intermediate, >125 nmol/L (>50 mg/dL) high.
More on Lp(a) ↓Less ↑
How to measure it
- Ask for lipoprotein(a) once; it is set by your genes and rarely changes.
- Enter the value with the unit the lab used, nmol/L or mg/dL; the two are not interchangeable.
hs-CRPmg/L
Low-grade inflammation in blood vessels
Values above 10 mg/L usually reflect acute infection or inflammation rather than chronic cardiovascular risk — the AHA/CDC statement advises discarding the result and re-testing once well.
In range
- Low: < 1
- Average: 1–3
- High: > 3
- Re-test: ≥ 10
Repeat
—
Line drawn by
AHA/CDC Scientific Statement on markers of inflammation and cardiovascular disease (Pearson TA et al, Circulation 2003;107:499-511). Relative cardiovascular risk bands: <1.0 mg/L low, 1.0-3.0 mg/L average, >3.0 mg/L high.
More on hs-CRP ↓Less ↑
How to measure it
- Ask for high-sensitivity CRP, not the ordinary CRP.
- Skip it during a cold, an injury or the week after a hard race; it rises with any inflammation.
- Enter in mg/L as printed.
Waist & phenotype
Waistcm
The tape, and the two ratios it produces
A tape measure, used properly, captures cardiovascular risk that BMI misses. Verve leads with waist-to-height, because it needs only the waist and the height already on file.
In range
- In range: < 94 cm
- Elevated: ≥ 94 cm
Repeat
Whenever you measure.
No guideline names an interval for a tape measure
Line drawn by
IDF 2006 ethnicity-adjusted cutoffs.
More on Waist ↓Less ↑
How to measure it
- WAIST — stand with your feet together, tape directly on skin.
- Place the tape over the top of your hip bone (the iliac crest).
- Keep it snug but not compressing, and level all the way around.
- Read it at the end of a normal breath out. Don't hold your breath or pull your stomach in.
- Use the same landmark every time — small differences move you between risk categories.
- HIP — feet still together, tape around the widest part of your buttocks, level all the way around.
BMI misses the normal-weight person carrying dangerous visceral fat — thin outside, fat inside (TOFI) — and it falsely flags the person with obesity whose fat distribution is otherwise benign. Among adults BMI classified as normal weight, 18% had an elevated waist-to-hip ratio: central adiposity BMI did not account for. Among those classified as having obesity, about 45% had a low waist-to-hip ratio — BMI called them high risk, and their fat distribution did not agree.
WHAT ELEVATED CENTRAL ADIPOSITY CARRIES. For adults of normal weight or overweight, an elevated waist circumference or waist-to-hip ratio carried 15% to 50% greater risk across the cardiovascular outcomes studied. The largest relative increases were for all-cause death and cardiovascular disease.
Attributable burden is a different question from relative risk. Among people WITH OBESITY, 49% of heart failure events, 46% of atrial fibrillation events and 36% of coronary heart disease mortality were attributable to elevated waist circumference.
WHEN BMI AND THE TAPE DISAGREE. Among people with obesity, a low WAIST CIRCUMFERENCE was not simply neutral: it translated into lower all-cause mortality, with no other outcome differing materially.
The sex difference is a WAIST-TO-HIP finding, not a waist-circumference one — the metric changes here, and the change matters. Men with obesity and a low waist-to-hip ratio were not risk-free: atrial fibrillation remained elevated compared with men who had both normal weight and a low ratio. Women with obesity and a low waist-to-hip ratio remained at higher risk across all cardiovascular outcomes than normal-weight women with a low ratio.
WHAT THIS DOES NOT SAY. Dardari and colleagues report observational data. It shows that waist circumference and waist-to-hip ratio reclassify cardiovascular risk beyond BMI. It does not show that deliberately reducing either causally lowers cardiovascular events; residual confounding cannot be excluded, and no cause-and-effect relationship can be established from this design. The biology makes it plausible; the study does not make it proven.
MEASURING IT THE SAME WAY EVERY TIME. Small variations in technique move someone between risk categories, so standardisation matters more here than in almost any other measurement in this app. Waist: stand with feet together, and pass a non-stretch tape around the abdomen over the top of the iliac crest, snug without compressing. Read at the end of a normal breath out, and use the same landmark for every follow-up. Hip: stand with feet together, and pass the tape around the widest girth at the level of the buttocks.
THE TWO RATIOS. Waist-to-height ratio is waist ÷ height. Waist-to-hip ratio is waist ÷ hip. Both sides in the same unit — centimetres or inches, but not one of each. Verve leads with waist-to-height because it needs only the waist and the height already on record, so it appears the moment a waist is measured; waist-to-hip needs a second tape measurement nothing can supply automatically, and is offered as the complementary reading. Both are shown on the waist card itself, beside the tape that produced them.
MEASURING YOUR HIP. Stand with your feet together. Pass a non-stretch tape around the widest girth at the level of the buttocks, level all the way around and snug without compressing. There is no reference range for a hip on its own and Verve does not offer one — a hip means something only as the second half of the ratio.
THE CUT-OFFS BELOW ARE THE WHO AND IDF CONSENSUS VALUES, NOT THE PAPER'S. Dardari and colleagues defined high waist and high waist-to-hip ratio within their own cohorts; the thresholds Verve judges your measurement against are the standard clinical ones. Waist circumference: 102 cm (40 in) men, 88 cm (35 in) women in the general population; 90 cm (35 in) men, 80 cm (31.5 in) women in Asian populations. Waist-to-hip: 0.90 men, 0.85 women. Waist-to-height: 0.50 for everyone. Only waist circumference has ethnicity-specific cut-offs — waist-to-hip and waist-to-height do not, and no guideline publishes ancestry-adjusted versions of them.
Verve applies the IDF metabolic-syndrome waist cut-off (94 cm men, 90 cm men of Asian ancestry, 80 cm women) inside the metabolic-syndrome tally, because that is the number the Alberti 2009 criteria are written against. The higher WHO figures above describe substantially increased cardiovascular risk. They are two questions, and they have two published answers.
References
- Dardari ZA, Yao Z, Zhang J, et al. Risk Reclassification Beyond BMI by Waist Circumference and Waist-to-Hip Ratio Across 9 Cardiovascular Outcomes: Results From the Cross-Cohort Collaboration. Journal of the American College of Cardiology. 2026.
- WHO Expert Consultation. Waist Circumference and Waist-Hip Ratio: Report of a WHO Expert Consultation, Geneva, 8-11 December 2008. World Health Organization, 2011.
- Ashwell M, Gunn P, Gibson S. Waist-to-height ratio is a better screening tool than waist circumference and BMI for adult cardiometabolic risk factors: systematic review and meta-analysis. Obesity Reviews. 2012.
- National Institute for Health and Care Excellence. Obesity: identification, assessment and management. NICE guideline CG189, 2022 update.
- Alberti KGMM, Eckel RH, Grundy SM, et al. Harmonizing the Metabolic Syndrome: A Joint Interim Statement. Circulation. 2009.
Muscle health
Lean Mass (arms + legs)kg
Muscle on your arms and legs, from a DXA scan
Arms + legs lean mass, read straight off a DXA report — not Apple Health's lean mass, which is whole-body and roughly twice this. Judged as ALMI (ALM ÷ height²), the form EWGSOP2 writes its cut-offs against.
In range
- In range: ≥ 21.4 kg
- Low: < 21.4 kg
Repeat
every 6 monthsVerve’s own
Verve's own cadence, anchored to EWGSOP2 2019
Line drawn by
EWGSOP2 (Cruz-Jentoft 2019) · AWGS 2019 (Chen 2020) for Asian cut-offs.
More on Lean Mass (arms + legs) ↓Less ↑
How to measure it
- Open your DXA report and find the appendicular or arms+legs lean mass.
- It is the sum of the four limbs, in kilograms — not total lean mass.
- Enter that figure; Verve divides it by your height squared to get ALMI.
EWGSOP2 does not define a cut-off for FFMI — fat-free mass index is not part of its algorithm at all. Its muscle-mass criterion is appendicular lean mass (ALM) and its height-indexed form, ALMI, measured by DXA. Appendicular means the limbs: EWGSOP2 isolates arm and leg lean mass because it reflects the skeletal muscle that carries strength and mobility, excluding trunk lean mass, which includes organs.
The algorithm is sequential, and the order is the point: STRENGTH DEFINES IT, MASS CONFIRMS IT, PERFORMANCE GRADES IT. Low grip strength identifies PROBABLE sarcopenia; low ALM or ALMI CONFIRMS it; and low physical performance — gait speed or Timed Up and Go — grades it as SEVERE. Low muscle mass on its own is not sarcopenia under EWGSOP2, which is why Verve never reports it as such.
EWGSOP2 thresholds. Grip strength: <27 kg men, <16 kg women — defines probable sarcopenia. ALM absolute: <20 kg men, <15 kg women — the alternative mass threshold, used when height is not on file. ALMI (ALM ÷ height², DXA): <7.0 kg/m² men, <5.5 kg/m² women — confirms. Gait speed (4 m usual pace): ≤0.8 m/s — severity. Timed Up and Go: ≥20 s — alternative to gait speed.
The women's ALMI cut-off differs by guideline AND by measurement, and the two must not be mixed: EWGSOP2 reads <5.5 kg/m² by DXA, while AWGS reads <5.4 kg/m² by DXA and <5.7 kg/m² by BIA. Verve applies the DXA figure, because ALM is entered from a DXA report.
References
- Cruz-Jentoft AJ, et al. Sarcopenia: revised European consensus on definition and diagnosis (EWGSOP2). Age and Ageing. 2019.
- Chen LK, et al. Asian Working Group for Sarcopenia: 2019 consensus update. JAMDA. 2020.
- Chen LK, Hsiao FY, Akishita M, et al. A focus shift from sarcopenia to muscle health in the Asian Working Group for Sarcopenia 2025 Consensus Update. Nature Aging. 2025.
- de Santana FM, Domiciano DS, Gonçalves MA, et al. Association of Appendicular Lean Mass, and Subcutaneous and Visceral Adipose Tissue With Mortality in Older Brazilians: The São Paulo Ageing & Health Study. Journal of Bone and Mineral Research. 2019.
- Westerterp KR, Yamada Y, Sagayama H, et al. Physical activity and fat-free mass during growth and in later life. The American Journal of Clinical Nutrition. 2021.
- Jagim AR, Harty PS, Jones MT, et al. Fat-Free Mass Index in Sport: Normative Profiles and Applications for Collegiate Athletes. Journal of Strength and Conditioning Research. 2024.
- Olshvang D, Harris C, Chellappa R, Santhanam P. Predictive modeling of lean body mass, appendicular lean mass, and appendicular skeletal muscle mass using machine learning techniques: NHANES and the Look AHEAD study. PLoS One. 2024.
Grip strengthkg
Whole-body strength, measured at the hand
In range
- In range: ≥ 27 kg
- Low: < 27 kg
Repeat
—
Line drawn by
EWGSOP2 (Cruz-Jentoft 2019) — sarcopenia case-finding.
More on Grip strength ↓Less ↑
How to measure it
- Sit with your elbow at 90°, forearm neutral, wrist straight.
- Squeeze the dynamometer as hard as you can for 3 seconds.
- Take 3 attempts per hand with a short rest between.
- Enter your single best result from either hand.
Body fat%
Share of body mass that is fat
Whole-body fat-free mass ÷ height², computed from your body fat %, weight and height. A NUTRITION measure, not a sarcopenia one: EWGSOP2 and AWGS do not use FFMI at all — they use ALM and ALMI, which isolate limb muscle, while fat-free mass includes the trunk and its organs.
In range
- In range: 8–24.9%
- Borderline: 25–28.9%
- Low: < 8%
- Elevated: ≥ 29%
Repeat
—
Line drawn by
ESPEN/EASO 2022 — sarcopenic obesity; WHO thresholds below age 40.
More on Body fat ↓Less ↑
How to measure it
- Use the same method each time: a DXA scan, a bioimpedance scale or calipers; methods disagree by several points.
- Measure in the morning, before food, after the bathroom.
- Enter the percentage.
FFMI cut-offs exist within NUTRITION frameworks, not within the muscle-strength ones. ESPEN and GLIM both define them; EWGSOP2's sarcopenia algorithm does not use FFMI at all, relying on ALM and ALMI instead.
ESPEN 2015 consensus criteria for malnutrition (DXA-derived FFMI): low is <17 kg/m² in men and <15 kg/m² in women. FFMI is used only as an ALTERNATIVE to reduced BMI, and only once unintentional weight loss is present — more than 10% at any time, or more than 5% over three months. Neither FFMI nor BMI alone diagnoses malnutrition.
GLIM 2019 uses the same FFMI thresholds as its reduced-muscle-mass phenotypic criterion — <17 kg/m² men, <15 kg/m² women, equivalent to ALMI <7.0 and <5.5 per EWGSOP2. A diagnosis requires that phenotypic criterion PLUS at least one etiologic criterion: reduced intake or assimilation, or disease-related inflammation.
These cut-offs were validated by DXA in the SarcoPhAge cohort and were associated with increased mortality in malnourished older adults.
Separately, population screening studies using BIA-derived FFMI have proposed surrogate thresholds of 17.5–18 kg/m² in men and 14.4–15 kg/m² in women, correlating with DXA-defined low ALMI in Japanese cohorts, with one linking low FFMI to increased fall risk. These are research-derived and ethnicity-specific — not formal guideline cut-offs — so Verve classifies against ESPEN/GLIM and names them here rather than applying them silently.
References
- Cederholm T, Bosaeus I, Barazzoni R, et al. Diagnostic Criteria for Malnutrition — An ESPEN Consensus Statement. Clinical Nutrition. 2015.
- Sanchez-Rodriguez D, Locquet M, Reginster JY, et al. Mortality in malnourished older adults diagnosed by ESPEN and GLIM criteria in the SarcoPhAge study. Journal of Cachexia, Sarcopenia and Muscle. 2020.
- Cederholm T, Bosaeus I. Malnutrition in Adults. The New England Journal of Medicine. 2024.
- Kawakami R, Tanisawa K, Ito T, et al. Fat-Free Mass Index as a Surrogate Marker of Appendicular Skeletal Muscle Mass Index for Low Muscle Mass Screening in Sarcopenia. JAMDA. 2022.
- Takagi S, Maeda K, Satake S, et al. Fat-Free Mass Index Cutoff Values for Reduced Muscle Mass in Older Community-Dwelling Adults in Japan: A Descriptive Cohort Study. JPEN. 2025.
- Yin L, Cao Y, Tang M, et al. Operationalizing the Global Leadership Initiative in Sarcopenia: Muscle-Specific Strength, Optimal Criteria and Clinical Relevance. Journal of Cachexia, Sarcopenia and Muscle. 2026.
Whole-body lean masskg
Everything except fat, from your body fat and weight
In range
—
Repeat
—
Line drawn by
Fat-free mass from body fat and weight, plus the essential fat every body carries (3% men, 5% women).
More on Whole-body lean mass ↓Less ↑
How to measure it
- From a DXA report, or a bioimpedance scale that prints lean or fat-free mass.
- Same method, same morning conditions each time.
- Enter in kg.
Muscle mass%
Share of body mass that is skeletal muscle
Skeletal muscle percentage, as reported by a BIA scale.
In range
—
Repeat
—
Line drawn by
Janssen et al. 2000 (NHANES) with BIA population survey norms.
More on Muscle mass ↓Less ↑
How to measure it
- From a bioimpedance scale or a DXA report that prints skeletal muscle as a share of weight.
- Same method, same morning conditions each time.
- Enter the percentage.
Single-leg balanceseconds
How long you can stand on one leg
In range
- Good: At or above the age norm
- Fair: Below the age norm
- Impaired: Under 10 s
Repeat
—
Line drawn by
Araujo et al. 2022 — 10-second one-leg stand and survival.
More on Single-leg balance ↓Less ↑
How to measure it
- Stand on one leg, eyes open, hands on hips or by your sides.
- Start timing when you lift the other foot clear of the floor.
- Stop when you put the foot down, hop, or grab support.
- Stand near a wall or chair you can reach for safety.
Chair standseconds
Time to rise from a chair five times
In range
- Good: At or under the age norm
- Fair: Over the age norm
- Impaired: Over 15 s
Repeat
—
Line drawn by
EWGSOP2 — 5-repetition sit-to-stand.
More on Chair stand ↓Less ↑
How to measure it
- Use a standard chair against a wall; arms folded across your chest.
- Stand fully upright and sit back down — that is one repetition.
- Time 5 complete repetitions as fast as you safely can.
SPPB
Balance, walking speed and chair stand, scored together
The Short Physical Performance Battery — three timed tests scored 0-4 each, totalling 0-12. Verve works the score out from the balance, walking-speed and chair-stand results you record; there is nothing to type.
In range
- Good: 10–12
- Intermediate: 7–9
- Poor: ≤ 6
Repeat
—
Line drawn by
Guralnik JM et al, J Gerontol 1994;49(2):M85-94 — the SPPB.
More on SPPB ↓Less ↑
How to measure it
- Do the three tests in one session: the side-by-side, semi-tandem and tandem stands, each held up to 10 seconds; the 4-metre walk at your usual pace; five rises from a chair without using your arms.
- Enter each test's result; the 0 to 12 score is worked out from them.
SPPB stands for the SHORT PHYSICAL PERFORMANCE BATTERY. It was developed for the US National Institute on Aging's EPESE studies and published by Guralnik and colleagues in 1994, and it is the most widely used measure of lower-body function in older adults. Three tests — standing balance, walking speed, and rising from a chair — each score 0 to 4, and the three add to a total out of 12.
It matters because it predicts things a single measurement does not. Lower SPPB scores are associated with disability, hospitalisation, nursing-home admission and mortality, and EWGSOP2 uses the battery as one of its measures of physical performance — the step that grades sarcopenia as SEVERE once low strength and low muscle mass have already been established.
HOW TO DO IT — 1. BALANCE. Three stands, each held up to 10 seconds, done in order and stopped as soon as one is failed. Feet side by side, touching. Then semi-tandem: the heel of one foot beside the big toe of the other. Then full tandem: one heel directly in front of the other toes, as though on a line. Stand near a wall or a helper, arms free, and stop the clock the moment you move your feet or grab support. Score: 0 if side-by-side is not held for 10 s; 1 if side-by-side is held but semi-tandem is not; 2 if tandem is held under 3 s; 3 if tandem is held 3 to 9 seconds; 4 if tandem is held the full 10 s.
HOW TO DO IT — 2. WALKING SPEED. Mark a straight 4-metre course with clear space to start and stop. Walk it at your USUAL pace, not your fastest — this is the pace you would use crossing a room, and walking fast is the commonest way to get an unrepresentative result. Use a walking aid if you normally use one. Time from first movement to when the leading foot crosses the 4 m line, take the better of two attempts, and enter the speed in metres per second (4 divided by your time in seconds). Score: 4 if it takes under 4.82 s, 3 up to 6.20 s, 2 up to 8.70 s, 1 if slower.
HOW TO DO IT — 3. CHAIR STAND. Use a straight-backed chair against a wall. Fold your arms across your chest — no pushing off with hands, which is what makes this a leg test — and stand fully upright and sit down five times as fast as you safely can. Time all five repetitions. If you cannot do one without using your arms, the score is 0. Score: 4 under 11.2 s, 3 up to 13.6 s, 2 up to 16.6 s, 1 up to 60 s, 0 beyond that.
READING THE TOTAL. 10 to 12 is good function. 7 to 9 is intermediate and is where the risk curve starts to bend. 6 or below is poor and is the range most strongly associated with subsequent disability. A change of about 1 point is generally taken as the smallest meaningful change, so the number is worth repeating every few months rather than watching week to week.
SAFETY. Every part is optional and every part can be stopped. Do the balance stands within reach of something solid, and skip any test that feels unsafe on the day — a missing score is honest, and a fall is not worth a number.
References
- Guralnik JM, Simonsick EM, Ferrucci L, et al. A short physical performance battery assessing lower extremity function: association with self-reported disability and prediction of mortality and nursing home admission. Journal of Gerontology. 1994;49(2):M85-94.
- Guralnik JM, Ferrucci L, Simonsick EM, et al. Lower-extremity function in persons over the age of 70 years as a predictor of subsequent disability. New England Journal of Medicine. 1995;332(9):556-61.
- Cruz-Jentoft AJ, et al. Sarcopenia: revised European consensus on definition and diagnosis (EWGSOP2). Age and Ageing. 2019;48(1):16-31.
- Perera S, Mody SH, Woodman RC, Studenski SA. Meaningful change and responsiveness in common physical performance measures in older adults. Journal of the American Geriatrics Society. 2006;54(5):743-9.
Walk speedm/s
Your usual walking pace
In range
- Good: ≥ 1.2 m/s
- Average: 1.0-1.2 m/s
- Below: 0.8-1.0 m/s
- Impaired: < 0.8 m/s
Repeat
—
Line drawn by
EWGSOP2 — usual-pace 4-metre gait speed.
More on Walk speed ↓Less ↑
How to measure it
- Mark a 4-metre straight course with clear space at both ends.
- Walk it at your usual comfortable pace, not a fast one.
- Divide 4 by your time in seconds to get metres per second.